At Moderna, we take corporate social responsibility (CSR) seriously. Our company policies and recent data demonstrate our commitment to transparency and serve to hold us accountable as we continue to develop potentially life-changing medicines.


These policies highlight our responsibility to patients, employees, the environment and local communities. They allow us to integrate corporate responsibility into efforts across our business landscape and employee experience.

Access to Medicine

We’re committed to optimizing the impact of mRNA vaccines and therapeutics through fair pricing and access for all.
Read Our Access Statement
Read Our IP Statement

Human Rights

As a company at the forefront of developing medicines for patients across the world, we have an obligation to purposefully uphold human rights.
Read Our Policy

Political Engagement Policy

We do not make direct contributions to political campaigns or candidates, and are committed to transparency on our engagement with trade associations and other advocacy organizations.

Read our Political Policy and Disclosure

Code of Business Conduct & Ethics

Ensuring all employees act ethically and legally in their business decisions and day-to-day duties is crucial to carrying out our mission. 

Read Our Code

Corporate Governance Guidelines

We believe sound governance practices and policies are important to our success as a company and to obtaining the trust of our stakeholders.

Read Our Guidelines

2018 Citizenship Framework

Our 2018 Corporate Social Responsibility (CSR) whitepaper, which laid out the framework for the core focus areas of our CSR program.

Read Our Whitepaper

CEO Action for Diversity & Inclusion Pledge

We’ve pledged to act on supporting more inclusive workplaces because we know that success is rooted in diverse viewpoints.

Read the Pledge

U.S. Employee Benefits

Moderna team members drive our advancements toward bringing innovative medicines to patients. Our commitment to them is rooted in an inclusive environment that fosters well-being.

U.S. Employee Benefits Update

Government Funding and Vaccine Access

Learn more about how we have approached access and pricing for our COVID-19 vaccine, including as a result of government funding.

Government Funding and Vaccine Access


Our data show the strides we’re making at Moderna. 

 R&D investments

  2018 2019 2020
R&D Expenses $454 million $496 million $1,370 million
R&D as a percentage of Total Operating Expenses 83% 82% 87%

 Gender & ethnicity

  2018 2019 2020
Percentage of workforce who are women 44% 46% 46%
Percentage of leadership (VP and above) who are women 29% 35% 37%
Percent of workforce who are racially/ethnically diverse (U.S. only) 32% 32% 35%